# 2026-23413: FDA Eyes Flolipid Approval After Company Misses Annual Reports

2026-23413, Salerno Pharmaceuticals; Proposal To Withdraw Approval of a New Drug Application for Flolipid Suspension, 20 Milligrams/5 Milliliters and 40 Milligrams/5 Milliliters; Opportunity for a Hearing, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-11-18, effective The NDA holder may submit a request for a hearing by December 18, 2026. Submit all data, information, and analyses upon which the request for a hearing relies by January 19, 2027. Electronic or written comments may be submitted by January 19, 2027.; PRIA reads it as touching household money (as of 2026-11-18).

- Canonical: https://policyrisk.com/federal-register/2026-23413
- As of: 2026-11-18
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-23413
- Title: Salerno Pharmaceuticals; Proposal To Withdraw Approval of a New Drug Application for Flolipid Suspension, 20 Milligrams/5 Milliliters and 40 Milligrams/5 Milliliters; Opportunity for a Hearing
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 74176
- Published: 2026-11-18
- Effective: The NDA holder may submit a request for a hearing by December 18, 2026. Submit all data, information, and analyses upon which the request for a hearing relies by January 19, 2027. Electronic or written comments may be submitted by January 19, 2027.
- Comments close: 2027-01-19
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-11-18

## In one line

FDA Eyes Flolipid Approval After Company Misses Annual Reports

## Summary

The FDA plans to pull the approval for Salerno Pharmaceuticals' Flolipid Suspension because the company hasn’t submitted required yearly reports. Salerno has until December 18, 2026, to ask for a hearing to explain themselves. This affects anyone using or selling Flolipid and could change its availability soon.

## Abstract

The Food and Drug Administration's (FDA or Agency) Center for Drug Evaluation and Research (CDER) is proposing to withdraw approval of new drug application (NDA) 206679 for Flolipid suspension, 20 milligrams (mg)/5 milliliters (mL) and 40 mg/5 mL and is announcing an opportunity for the NDA holder, Salerno Pharmaceuticals, 2431 East 61st St., Suite 300, Tulsa, OK 74136, to request a hearing on this proposal. The basis for the proposal is that Salerno Pharmaceuticals has repeatedly failed to file required annual reports for NDA 206679.

## Effects PRIA read

- FDA proposes to withdraw Flolipid approval: cost, medium. The FDA is proposing to withdraw approval of NDA 206679 for Flolipid suspension (20 mg/5 mL and 40 mg/5 mL) because Salerno Pharmaceuticals repeatedly failed to file required annual reports under 21 CFR 314.81. If approval is withdrawn, the Flolipid products covered by this NDA may not be lawfully…
- Opportunity to seek hearing and submit evidence: benefit, low. Salerno Pharmaceuticals may request a hearing on the proposed withdrawal by December 18, 2026, and must submit all supporting data and analyses by January 19, 2027. Other interested persons may submit electronic or written comments by January 19, 2027; confidential submissions have special paper-su…

## Related documents

- [2026-23351](https://policyrisk.com/federal-register/2026-23351): Rulemaking To Provide That N-acetyl-L-cysteine Is Not Excluded From the Dietary Supplement Definition, 2026-11-17
- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25

## Sources
- [2026-23413 on federalregister.gov](https://www.federalregister.gov/documents/2026/11/18/2026-23413/salerno-pharmaceuticals-proposal-to-withdraw-approval-of-a-new-drug-application-for-flolipid)
- [2026-23413 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-11-18/pdf/2026-23413.pdf)

## Related
- [Previous: 2026-23412, Applications for Inclusion on the Binational Panels Roster Under the United Sta…](https://policyrisk.com/federal-register/2026-23412)
- [Next: 2026-23414, Determination That BROMFED-DM (Brompheniramine Maleate; Dextromethorphan Hydrob…](https://policyrisk.com/federal-register/2026-23414)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-23413 (as of 2026-11-18).
